

# **Average Proteinuria Grade Combined SLE Experiments +/- SEM**




FIGURE 1

## Dosing Protocol













SLE-5	Treatment, 3x/wk, Subcutaneously	Age (weeks)																	
		25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40		
A	5 mg/kg Rapamycin (AY-22889-21)																		
B	200 ug/ms anti-murine B7.1																		
	200 ug/ms anti-murine B7.2																		
C	5 mg/kg Rapamycin (AY-22889-21)																		
	200 ug/ms anti-murine B7.1																		
	200 ug/ms anti-murine B7.2																		
D	5 mg/kg Rapamycin (AY-22889-21)																		
E	5 mg/kg Rapamycin (AY-22889-21)																		
	200 ug/ms anti-murine B7.1																		
	200 ug/ms anti-murine B7.2																		
F	200 ug/ms anti-murine IL-12																		
G	Vehicle																		

FIGURE 2

97 JPS-002 SLE-7 Histopathologic Evaluation of NZB x NZW F1 Hybrid Female Mice

42 weeks of age

Group	Animal	Spleen	Spleen	Kidney	Kidney	Kidney
No Therapy		Lymphoid Hyperplasia	Hematopoiesis	Interstitial Inflammation	Glomerulonephritis Cellularity-Membrane Thickness	Tubular Dilatation
	1	-2	-3	+2	-2 +2	+3
	2	+2	+2	+3	-1 +3	+3
	3	+2	+2	+2	-1 +3	+2
	4	+2	+2	+3	-3 +3	+4
	5	+2	+3	+3	-3 +3	+4
	Mean	+1.2	+1.2	+2.6	-2.0 +2.8	+3.2
<i>Rapamycin</i>						
(Treatment Weeks 29-36)						
	1	+1	+1	(+1)	0 +1	+1
	2	+1	+1	(+1)	0 +1	0
	3	+1	+1	(+2)	0 0	0
	4	+1	+1	0	0 0	0
	5	+1	+1	(+1)	0 0	0
	Mean	+1.0	+1.0	+1.0	0 +0.4	+0.2

Histologic Grades

0 = Normal  
 1 = Slight  
 2 = Mild  
 3 = Moderate  
 4 = Marked  
 5 = Severe  
 () = Focal not Diffuse

Histopathologic Assessment : Elizabeth Goad, PhD, DVM.

FIGURE 3




FIGURE 4A




FIGURE 4B

A.

## Single Therapeutic Dosing




FIGURE 5A

B.

## Combined Therapeutic Dosing




FIGURE 5B